natgillin/translations-raw huggingface dataset:
The compound or composition for use in the method of claim 9, wherein the condition is female sexual dysfunction and the method further comprises administering a compound or compounds selected from a group consisting of estradiol, estriol, estradiol esters, progesterone and progestins to a patient in need thereof. 
Spoj ili pripravak za uporabu u postupku prema zahtjevu 9, gdje je stanje seksualna disfunkcija u žena i postupak dalje obuhvaća primjenu spoja ili spojeva izabranih iz grupe koja obuhvaća estradiol, estriol, estere estradiola, progesteron i progestine bolesniku kojemu je to potrebno.
A PARP inhibitor or a therapeutically acceptable salt thereof, wherein the PARP inhibitor is 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, for use in treating cancer or inhibiting tumor growth in a mammal, wherein the cancer is a CNS tumor, and wherein said PARP inhibitor is to be administered in combination with radiotherapy. 
Inhibitor PARP-a ili njegova terapijski prihvatljiva sol, naznačen time, da je inhibitor PARP-a 2-[(2R)-2-metilpirolidin-2-il]-1H-benzimidazol-4-karboksamid namijenjen liječenju karcinoma ili sprječavanju rasta tumora u sisavca, pri čemu je karcinom tumor središnjeg živčanog sustava, a navedeni inhibitor PARP-a primjenjuje se u kombinaciji s radioterapijom.
is selected from H, alkyl, heteroalkyl, and arylalkyl; and R2 and R3 together with the nitrogen group form an aliphatic amine. 
je izabran od H, alkil, heteroalkil i arilalkil grupe; i i R3 uzeti zajedno sa dušikovom grupom formiraju alifatični amin.
The compound of claim 1 wherein R2 is selected from methylene, ethylene, propylene, or butylene. 
Spoj prema patentnom zahtjevu 1 naznačen time što je R2 izabran od metilena, etilena, propilena ili butilena.
The compound for use of claim 14, wherein the cancer is cancer of the prostate, lung, breast and colon. 
Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što je kancer – kancer prostate, pluća, dojke i debelog crijeva.
The pharmaceutical composition of claim 16 further comprising a pharmaceutically acceptable carrier or agent. 
Farmaceutska kompozicija prema patentnom zahtjevu 16 naznačena time što dalje sadrži farmaceutski prihvatljiv nosač ili sredstvo.
represents C1-C4alkylene, C2-C4alkenylene, >C=O or a group selected from-C2H4NH-, -C2H4O-, and -C2H4S- being linked to the adjacent NR5-group via the carbon atom; and G represents aryl or heteroaryl, which is unsubstituted or substituted and 
predstavlja C1-C4alkilen, C2-C4alkenilen, >C=O ili skupinu koju se bira između -C2H4NH-, -C2H4O- i -C2H4S-, koji su vezani na susjednu skupinu NR5- preko atoma ugljika; i G predstavlja aril ili heteroaril, koji je nesupstituiran ili supstituiran; i
R3, R4 and R5 independently of one another, represent hydrogen or C1-C6alkyl; 
, R4 i R5, međusobno neovisno, predstavljaju vodik ili C1-C6alkil;
and X2 independently of one another, represent a nitrogen atom or CR2, with the proviso that at least one of X1 and X2 represents a nitrogen atom; 
i X2, međusobno neovisno, predstavljaju a atom dušika ili CR2, uz uvjet da najmanje jedan od X1 i X2 predstavlja atom dušika;
represents a nitrogen atom and 
predstavlja atom dušika; i
represents a group CR2, in particular CH. 
predstavlja skupina CR2, a osobito CH.
is a cyclohexylene group or saturated and unsaturated 4 to 6-membered heterocyclodiyl with 1 or 2 nitrogen atoms as heteroatoms. 
je cikloheksilenska skupina ili zasićen i nezasićen 4 do 6-eročlani heterociklodiil s 1 ili 2 atoma dušika kao heteroatomima.
is selected from: wherein * indicates the bond to the (CH2)n group in formula (I). 
[image] [image] gdje * označuje vezu na skupinu (CH2)n u formuli (I).
represents C1-C4alkylene, -C(=O)- or a group -C2H4S- being linked to the adjacent NR5-group via the carbon atom; 
predstavlja C1-C4alkilen, -C(=O)- ili skupinu -C2H4S- koji su vezani na susjednu skupinu NR5- preko atoma ugljika;
is selected from: wherein * indicates the bond to the (CH2)n group in formula (I). 
[image] gdje * označuje vezu na skupinu (CH2)n u formuli (I).
A process for the preparation of a compound of formula I as claimed in any one of claim 1 to 20, in particular in any one of claim 1 to 13, wherein a compound of formula IV is reacted with a compound of formula V to generate a compound of formula VI in which formulae 
Postupak dobivanja spoja formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 20, a osobito s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što spoj formule IV [image] reagira sa spojem formule V [image] kako bi se dobilo spoj formule VI [image], gdje formule
is as defined in formula I, E is an amino protecting group or a group of formula -A4-G, wherein 
je kao što je definirano u formuli I; E je zaštitna skupina za amino ili skupina formule -A4-G, gdje
and G have the same meaning as in formula I, and when L1 is nitro, the nitro group is reduced to an amino group and the amino derivative obtained is reacted with a compound of formula III G-A4b-L0 (III), wherein 
i G imaju isto značenje kao u formuli I; i kada je L1 nitro, nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat reagira sa spojem formule III G-A4b-L0 (III), gdje
b is absent or represents C1-C3alkylene, C1-C3alkenylene or a group selected from -CH2NH-, -CH2O-, and -CH2S-, said group being linked to G via the nitrogen, oxygen or sulfur atom; or when L1 is N(R5)E and E is an amino protecting group said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III as defined above. 
b je odsutan ili predstavlja C1-C3alkilen, C1-C3alkenilen ili skupinu koju se bira između -CH2NH-, -CH2O- i -CH2S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora; ili kada je L1 N(R5)E, a E je zaštitna skupina za amino, navedenu zaštitna skupina se uklanja, a međuprodukt s kojeg je skinuta zaštita reagira sa spojem formule III kao što je definirano gore.
is as defined in formula I, and E is an amino protecting group or a group of formula -A4-G, wherein 
je kao što je definirano u formuli I; i E je zaštitna skupina za amino ili skupina formule -A4-G, gdje
and G have the same meaning as in formula I; 
i G imaju isto značenje kao u formuli I;
the compound of formula IX is reduced to convert it to the compound of formula XI wherein A3, L1, R1, X1, X2, and n are as defined above; and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is reacted with a compound of formula III G-A4b-L0 (III), wherein 
gdje se spoj formule IX reducira kako bi ga se prevelo u spoj formule XI [image], gdje su A3, L1, R1, X1, X2 i n definirani kao gore; i kada je L1 nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat reagira sa spojem formule III G-A4b-L0 (III), gdje
is -O- or -N-R4, wherein a compound of formula XIII is reacted with a compound of formula XIV to generate a compound of formula XV in which formulae 
je -O- ili -N-R4, naznačen time što spoj formule XIII [image] reagira sa spojem formule XIV [image] kako bi se dobilo spoj formule XV [image], gdje formule
nitro or N(R5)E, is as defined in formula I, and E is an amino protecting group PG1 or a group of formula -A4-G, wherein 
je kao što je definirano u formuli I; i E je zaštitna skupina za amino, PG1, ili skupina formule -A4-G, gdje
is a halogen atom or -N(R4)PG2 wherein PG2 is an amino protecting group, said compound of formula XV is then converted to the compound of formula XVI wherein A1, A2, A3, X1, X2, L1, R1 and n are as defined above, and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is reacted with a compound of formula III G-A4b-L0 (III), wherein 
je atom halogena ili -N(R4)PG2, gdje je PG2 zaštitna skupina za amino, navedeni spoj formule XV se zatim prevodi u spoj formule XVI [image], gdje su A1, A2, A3, X1, X2, L1, R1 i n definirani kao gore, kada je L1 nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat reagira sa spojem formule III G-A4b-L0 (III), gdje
is as defined in formula I, and E is an amino protecting group PG1 or a group of formula -A4-G, wherein 
je kao što je definirano u formuli I; i E je zaštitna skupina za amino, PG1, ili skupina formule -A4-G, gdje
is a halogen atom, is CH2 or O, said compound of formula XIX is then converted to the compound of formula XX wherein A1, A2, A3, X1, X2, L1, R1 and n are as defined above, and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is then reacted with a compound of formula III G-A4b-L0 (III), wherein 
je CH2 ili O; gdje se navedeni spoj formule XIX zatim prevodi u spoj formule XX [image], gdje su A1, A2, A3, X1, X2, L1, R1 i n definirani kao gore; i kada je L1 nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat zatim reagira sa spojem formule III G-A4b-L0 (III), gdje
is selected from -CH2Y, -CHO, -COOH and -COCl, Y is mesylate, tosylate, triflate or halogen, and A4b is absent or represents C1-C3alkylene, C1-C3alkenylene or a group selected from -CH2NH-, -CH2O-, and -CH2S-, said group being linked to G via the nitrogen, oxygen or sulfur atom; or when L1 is N(R5)E and E is an amino protecting group said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III as defined above. 
Y je mesilat, tosilat, triflat ili halogen; i b je odsutan ili predstavlja C1-C3alkilen, C1-C3alkenilen ili skupinu koju se bira između -CH2NH-, -CH2O- i -CH2S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora; ili kada je L1 N(R5)E, a E je zaštitna skupina za amino, navedenu zaštitna skupina se uklanja, a međuprodukt s kojeg je skinuta zaštita reagira sa spojem formule III kao što je definirano gore.
is -CH2- wherein a compound of formula VII is reacted with a compound of formula XXII to generate a compound of formula XXIII in which formulae X1, X2, R1, A3 and n are as in formula I, L1 is nitro or N(R5)E, 
je -CH2-, naznačen time što spoj formule VII [image] reagira sa spojem formule XXII [image] kako bi se dobilo spoj formule XXIII [image], gdje su formule X1, X2, R1, A3 i n kao u formuli I; je nitro ili N(R5)E;
is as in formula I, and E is an amino protecting group PG1 or a group of formula -A4-G, wherein 
je kao u formuli I; i E je zaštitna skupina za amino, PG1, ili skupina formule -A4-G, gdje
is nitro or N(R5)E, R5 is as in formula I, and E is an amino protecting group PG1 or a group of formula -A4-G, wherein and G have the same meaning as in formula I, is -NHR3 or -N(R3)PG2 wherein PG2 is an amino protecting group, 
je kao u formuli I; i E je zaštitna skupina za amino, PG1, ili skupina formule -A4-G, gdje i G imaju isto značenje kao u formuli I; je -NHR3 ili -N(R3)PG2, gdje je PG2 zaštitna skupina za amino,
The compounds according to claim 30 or pharmaceutically acceptable salts thereof for use as a medicament for the treatment of bacterial infections caused by the following bacteria strains: Acinetobacter baurnannii, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis Streptococcus pyogenes; Enterobacter aerogenes; Enterobacter cloacae; Streptococcus pneumoniae. 
Spojevi u skladu s patentnim zahtjevom 30, ili njihove farmaceutski prihvatljive soli, naznačeni time što su namijenjeni upotrebi kao medikamenti za liječenje bakterijskih infekcija čiji su uzročnici sljedeći bakterijski sojevi: Acinetobacter baumannii, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphilococcus aureus, Staphilococcus epidermidis, Streptococcus pyogenes, Enterobacter aerogenes, Enterobacter cloacae, Streptococcus pneumoniae.
A formulation suitable for subcutaneous administration comprising 125mg/ml CTLA4Ig molecules, a sugar selected from the group consisting of sucrose, lactose, maltose, mannitol and trehalose and mixtures thereof, and a pharmaceutically acceptable aqueous carrier, wherein the formulation has a pH range of from 6 to 8 and a viscosity of from 9 to 20 mPa·s, and the weight ratio of sugar:protein is 1.1:1 or higher. 
Formulacija pogodna za subkutanu primjenu koja sadrži 125mg/ml CTLA4Ig molekule, šećer izabran iz grupe koju čine saharoza, laktoza, maltoza, manitol i trehaloza i njihove smjese, i farmaceutski prihvatljiv vodeni nosač, pri čemu formulacija ima pH opseg od 6 do 8 i viskozitet od 9 do 20 mPa·s, i težinski odnos šećera:proteina je 1.1:1 ili viši.
The formulation of claim 8 wherein the buffering agent is in an amount of at least 10 mM phosphate buffer. 
Formulacija prema patentnom zahtjevu 8, naznačena time što je puferujuće sredstvo u količini od najmanje 10 mM fosfatnog pufera.
The formulation according to claim 18 for use in the therapy of immune system diseases according to claim 18 wherein immune system diseases are selected from the group containing autoimmune diseases, immunoproliferative diseases, and graft-related disorders. 
Formulacija prema patentnom zahtjevu 18 za uporabu u liječenju bolesti imunološkog sustava prema patentnom zahtjevu18, pri čemu su bolesti imunološkog sustava izabrane iz grupe koju čine autoimune bolesti, imunoproliferativne bolesti i poremećaji povezani sa transplantom.
A device (10) for extracting energy from a liquid flow (100), the device (10) comprising: 
Uređaj (10) za crpljenje energije iz protoka tekućine (100), uređaj (10) obuhvaća:
A device according to claim 3, comprising a decompression chamber (22b) positioned downstream of the turbine (50) for enhancing a pressure differential across the turbine (50) during said return flow of liquid from the air compression chamber (24). 
Uređaj prema zahtjevu 3, obuhvaća dekompresijsku komoru (22b) smještenu nakon turbine (50) za povećanje diferencijala tlaka duž turbine (50) za vrijeme povratnog toka tekućine iz komore za kompresiju zraka (24).
A device according to claim 5, wherein the flap valves (40) comprise respective buoyant elements (42). 
Uređaj prema zahtjevu 5, gdje preklopni ventili (40) obuhvaćaju odgovarajuće plutajuće elemente (42).
A device according to claim 6, wherein the buoyant elements (42) have an angular displacement required to close the flap valves (40), the angular displacement increasing up the gradient. 
Uređaj prema zahtjevu 6, gdje plutajući elementi (42) imaju kutni pomak potreban za zatvaranje preklopnih ventila (40), kutni pomak povećava gradijent.
A device according to claim 6 or claim 7 wherein the buoyancy of the buoyant elements (42) increases up the gradient. 
Uređaj prema zahtjevu 6 ili zahtjevu 7 gdje plovnost plutajućih elemenata (42) povećava gradijent.
A network of devices comprising multiple devices (10) according to any one of the previous claims, wherein the multiple devices (10) are arranged or linked together to form said network of devices. 
Mreža uređaja koja se sastoji od više uređaja (10) prema bilo kojem od prethodnih zahtjeva, gdje je više uređaja (10) raspoređeno ili povezano međusobno da formiraju tu mrežu uređaja.
drying the absorptive layer and the topcoat, wherein the absorptive layer and the topcoat are either dried simultaneously or the absorptive layer is dried after step b) and before applying the topcoat according to step c) wherein the topcoat has a permeability of greater than 5.0×10-18 m2 and comprises calcium carbonate, and wherein the absorptive layer has an absorption rate from 1×10-5 ms-0.5 to 1×10-3 ms-0.5 and/or a volume uptake from 30 to 95 % by volume relative to the total volume of the absorptive layer. 
sušenje apsorpcijskog sloja i završnog premaza, pri čemu se apsorpcijski sloj i završni premaz suše ili istodobno ili se apsorpcijski sloj suši nakon koraka b) i prije nanošenja završnog premaza u koraku c) pri čemu završni premaz ima propusnost veću od 5.0×10-18 m2, i pri čemu apsorpcijski sloj ima stupanj upijanja od 1×10-5 ms-0.5 do 1×10-3 ms-0.5 i/ili unos volumena od 30 do 95 % volumena u odnosu na ukupni volumen apsorpcijskog sloja.
The method of claim 17, wherein steps b) to d) are also carried out on the reverse side of the base layer to manufacture a print medium being coated on the first side and the reverse side. 
Postupak prema zahtjevu 17, pri čemu se koraci b) do d) također provode na stražnjoj strani osnovnog sloja da se proizvede tiskovna podloga koja je premazana na prvoj strani i stražnjoj strani.
The method of claims 17 to 22, wherein the coating formulations are applied by high speed coating, meter size press, curtain coating, spray coating, or electrostatic coating, and preferably by high speed coating. 
Postupak prema zahtjevima 17 do 22, pri čemu se oblici premaza nanose premazivanjem pri visokoj brzini, film prešom, tekućom zavjesom, raspršivanjem ili elektrostatski, i poželjno premazivanjem pri visokoj brzini.
The method of any one of claims 1-4, wherein the weighting factor a is about 0.33. 
Postupak kod patentnog zahtjeva 1, gdje je težinski faktor a oko 0.33.
The method of any one of claims 1-5, wherein the first time point is within 1-7 days of the onset of symptoms in the subject. 
Postupak kod patentnog zahtjeva 1, gdje je prva zabilježena incidencija u periodu od 1-7 dana od pojave simptoma.
The antibody for use according to claim 8, wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, HER antibody, antibody directed against a tumor associated antigen, antihormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, liposomal doxorubicin, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD7200, a medicament that treats nausea, a medicament that prevents or treats skin rash or standard acne therapy, a medicament that treats or prevents diarrhea, a body temperature-reducing medicament, and a hematopoietic growth factor. 
Pertuzumab za uporabu prema zahtjevu 4, naznačen time, da je drugo terapeutsko sredstvo odabrano iz skupine koju čine: kemoterapeutsko sredstvo, HER-protutijelo, protutijelo usmjereno protiv antigena povezanog s tumorom, antihormonalni spoj, kardioprotektant, citokin, EGFR-ciljani lijek, anti-angiogensko sredstvo, inhibitor tirozin kinaze, COX-inhibitor, nesteroidni protuupalni lijek, inhibitor transferaze farnesila, protutijelo koje veže onkofetalni protein CA 125, HER2-cjepivo, HER-ciljana terapija, Raf-inhibitor ili ras-inhibitor, liposomalni doksorubicin, topotekan, taksan, dvostruki inhibitor tirozin kinaze, TLK286, EMD-7200, lijek koji sprečava mučninu, lijek koji sprečava ili liječi kožni osip ili standardna terapija za akne, lijek koji liječi ili sprečava proljev, lijek koji smanjuje tjelesnu temperaturu i hematopoietični faktor rasta.
survival is extended in the method, administration of the antibody extends TTP or survival at least about 20% more than TTP or survival achieved by administering an approved anti-tumour agent to the cancer patient. 
Pertuzumab za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se u postupku primjene pertuzumaba produljuje TTP ili preživljavanje barem 20% više nego što je TTP ili preživljavanje postignuto primjenom jednog odobrenog antitumorskog sredstva na pacijentu koji boluje od raka.
The antibody for use according to claim 13, wherein the antibody is pertuzumab, and wherein in the method administration of the antibody extends TTP or survival at least about 20% more than TTP or survival achieved by administering topotecan or liposomal doxorubicin to the patient. 
Pertuzumab za uporabu prema zahtjevu 13 ili zahtjevu 14, naznačen time, da se postupkom davanja pertuzumaba pacijentu produljuje TTP ili preživljavanje barem 20% više nego što je TTP ili preživljavanje postignuto primjenom topotekana ili liposomalnog doksorubicina kod pacijenta.
A compound having the following structure: or a pharmaceutically acceptable salt thereof, or a composition comprising the compound or pharmaceutically acceptable salt thereof and an excipient; for use in the treatment of a disease or disorder. 
Spoj, naznačen time, da je predstavljen sljedećom strukturom: [image] ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
The compound or composition for use according to claim 1, wherein the disease or disorder is bone cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je genitalno-urinarni rak.
The compound or composition for use according to claim 1, wherein the disease or disorder is hematologic cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je glioblastom.
The compound or composition for use according to claim 1, wherein the disease or disorder is a renal tumor. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je rak tankog crijeva.
The compound or composition for use according to claim 1, wherein the disease or disorder is a breast tumor. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je višestruki oblik glioblastoma.
A constraint film according to claim 4, characterised in that the supporting film (6) is made of biaxially oriented polypropylene. 
Film za učvršćivanje u skladu s patentnim zahtjevom 4, naznačen time, da je nosivi film (6) izrađen od dvoosno orijentiranog polipropilena.
Production method of a resin constraint film (1) to be used in the production of composite material artefacts (2); the method being characterised by comprising the steps of 
Postupak proizvodnje filma za učvršćivanje izrađenog od smole (1) koji se koristi u proizvodnji predmeta od kompozitnih materijala (2), naznačen time, da obuhvaća sljedeće korake:
realizing, via a vacuum vaporization deposition, a second layer (8) of coating material over the first layer (7) of release chemical product. 
nanošenje drugog sloja (8) materijala za oblaganje preko prvog sloja (7) za oslobađanje kemijskih proizvoda postupkom nanošenja isparavanjem u vakuumu.
A production method of a constraint film according to claim 12, characterised in that the supporting film (6) is made of biaxially oriented polypropylene. 
Postupak za proizvodnju filma za učvršćivanje u skladu s patentnim zahtjevom 12, naznačen time, da je nosivi film (6) izrađen od dvoosno orijentiranog polipropilena.
A production method of a constraint film according to any of claims 9 to 15, characterised in that the first layer (7) is formed by a layer of transparent or coloured paint with a thickness smaller than the thickness (d) of the supporting film (6). 
Postupak za proizvodnju filma za učvršćivanje u skladu s bilo kojim od patentnih zahtjeva 9 do 15, naznačen time, da je prvi sloj (7) izrađen od sloja prozirnog ili obojanog premaza debljine manje od debljine (d) nosivog filma (6).
Production method of composite material artefacts (2) formed by one or more overlapped layers of fibres (3) of organic or inorganic material, embedded in a matrix of thermosetting resin (4); the method being characterised by comprising, in sequence, 
Postupak za proizvodnju predmeta od kompozitnih materijala (2) dobivenih iz jednog ili više slojeva vlakana koji se preklapaju (3) iz organskog ili anorganskog materijala ugrađenih u matricu termostabilna smola (4), naznačen time, da navedenim slijedom obuhvaća sljedeće korake:
the step of realizing a semi-finished product (2') which follows the shape of the composite material artefact (2) to be manufactured, and which is formed by one or more layers of said fibres (3) impregnated with a thermosetting resin (4) still in a high viscosity liquid state; 
izrada poluproizvoda (2') u obliku budućeg proizvoda od kompozitnih materijala (2), koji se dobiva iz jednog ili više slojeva navedenih vlakana (3) impregniranih termostabilnom smolom (4) koja je još uvijek u tekućem stanju visoke viskoznosti,